Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Satralizumab plus baseline immunosuppressive therapy vs placebo in neuromyelitis optica and NMOSD
jRCT2080222347Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Dec 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in neuromyelitis optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) comparing Satralizumab arm with Placebo arm (2 arms). Primary endpoint: Time to first relapse (protocol-defined relapse). Started Dec 2013; status: completed.
02
Drugs
satralizumab
03
Conditions
neuromyelitis optica (NMO)Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on jRCT2080222347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222347.